Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
June 01, 2022
CLEVELAND, Ohio – Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2022 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could...
Continue ReadingApril 13, 2022
Dr. Tang, Stanford University, Harrington Scholar, is developing patidegib, a therapry that will hopefully be the first topical drug that is safe and efficacious for Basal Cell Carcinoma (BCC) tumors (skin cancer) prevention. Continue Reading
January 24, 2022
Linda and Les Vinney committed $1.25 million to establish the Linda and Les Vinney Scholar Program at Harrington Discovery Institute's Center for Brain Health Medicine, which will support new treatments for patients living with Alzheimer's disease. The gift also creates the Linda and Les Vinney Acceleration Awards, which will... Continue Reading
January 18, 2022
Four Medicines in Clinical Trials and More in the Pipeline When it came to vaccines being trialed to prevent COVID-19, University Hospitals was already at the national forefront of innovations advancing COVID-19 treatments in mid-2020.Now four Scholars at Harrington Discovery Institute at University Hospitals might well be... Continue Reading
November 16, 2021
CLEVELAND — In 2020, during the height of the COVID-19 Pandemic, Harrington Discovery Institute at University Hospitals put out a call to scientists around the world: Send us your ideas to battle the coronavirus and we may fund your research.They received three hundred applications.All they needed was a fraction of the money... Continue Reading
October 21, 2021
Researchers have discovered an approach that could prevent nerve cells in the brain from deteriorating after a traumatic brain injury (TBI).A research team including scientists with the Geriatric Research Education and Clinical Center at the Louis Stokes Cleveland VA Medical Center identified the approach for preventing nerve... Continue Reading
October 11, 2021
Dystonias are a group of chronic movement–disabling disorders for which highly effective oral medications or disease-modifying therapies are lacking. The availability of an oral drug with disease-modifying potential would transform the current treatment landscape. 2015 Harrington Scholar-Innovator Nicole Calakos, MD, PhD... Continue Reading
October 11, 2021
Metabolic syndrome is a cluster of conditions and includes obesity and can be dangerous as it increases the risk for heart disease, stroke, diabetes and other diseases. A Harrington Discovery Institute research team proves successful use of “anti-obesity” drug in pre-clinical animal models.“The last piece of the puzzle is... Continue Reading
October 11, 2021
Huntington’s Disease (HD) is a fatal neurological disorder caused by a trinucleotide CAG repeat expansion in the N-terminal exon 1 of the huntingtin (Htt) gene. HD manifests as uncontrolled involuntary movements accompanied by progressive motor and cognitive deficits, psychiatric disturbance, and dementia. There is no therapy... Continue Reading
August 19, 2021
Scientists on either side of the Atlantic have teamed up, through the new (OHC), to address unmet needs in rare disease research and deliver “major clinical impact” to patients.And now, the international collaboration between the University of Oxford, in England, and the Harrington Discovery Institute, in Cleveland, Ohio... Continue Reading
August 18, 2021
CLEVELAND—Metabolic syndrome is a cluster of conditions and includes obesity, and can be dangerous as it increases the risk for heart disease, stroke, diabetes and other diseases. In a recent study, published in , researchers at Harrington Discovery Institute at University Hospitals (UH) have discovered a therapeutic option... Continue Reading